Tamanho do Mercado de Terapia Fotodinâmica do Câncer na Ásia-Pacífico, Tendências, Relatório de Crescimento 2032

Asia Pacific Cancer Photodynamic Therapy Market

Tamanho do mercado em biliões de dólares

CAGR : 8.30 %

USD 738.34 Million USD 1,383.02 Million 2024 2032

Período de previsão	2025 –2032
Tamanho do mercado (ano base )	USD 738.34 Million
Tamanho do mercado ( Ano de previsão)	USD 1,383.02 Million
CAGR	8.30 %
Principais participantes do mercado	Novartis Pharma AG Galderma SA Bausch Health Companies Inc. Photocure ASA ADVANZ PHARMA Corp.

Mercado de Terapia Fotodinâmica para Câncer na Ásia-Pacífico, por Tipo de Produto (Medicamentos Fotossensibilizadores, Dispositivos de Terapia Fotodinâmica, Acessórios e Consumíveis), por Indicação de Câncer (Oncologia Cutânea e de Pele, Cabeça e Pescoço, Esôfago, Pulmão, Bexiga, Colo do Útero, Próstata), por Modalidade de Terapia (Terapia Isolada, Terapia Adjuvante, Terapia Paliativa, Terapia Combinada, Outras), por Técnica de Procedimento (Feixe Externo, Administração Intersticial, Administração Intracavitária, Administração Intraoperatória, Outras), por Estágio da Doença (Câncer em Estágio Inicial, Câncer em Estágio Avançado), por Perfil Demográfico do Paciente (Pediátrico, Adulto, Geriátrico), por Usuário Final (Hospitais, Clínicas de Dermatologia e Câncer de Pele, Centros Cirúrgicos Ambulatoriais, Institutos Acadêmicos e de Pesquisa, Outros), por Canal de Distribuição (Licitações Diretas, Distribuidores Terceirizados, Online, Outros) - Tendências e Previsões do Setor até 2032.

Tamanho do mercado de terapia fotodinâmica para câncer na região Ásia-Pacífico

O mercado de terapia fotodinâmica para o câncer na região Ásia-Pacífico foi avaliado em US$ 738,34 milhões em 2024 e deverá atingir US$ 1.383,02 milhões até 2032, com uma taxa de crescimento anual composta (CAGR) de 8,3% durante o período de previsão.
O mercado é impulsionado principalmente pela crescente prevalência do câncer, pelo aumento dos gastos com saúde e pela maior conscientização sobre opções de tratamento avançadas. Melhorias rápidas na infraestrutura de saúde e a expansão de centros especializados em tratamento de câncer também contribuem para esse cenário.
Esse crescimento é impulsionado por fatores como iniciativas governamentais que promovem o diagnóstico precoce e terapias inovadoras, o grande número de pacientes e o aumento dos investimentos de empresas internacionais e locais em tecnologias de terapia fotodinâmica.

Análise do Mercado de Terapia Fotodinâmica para Câncer na Região Ásia-Pacífico

O mercado de terapia fotodinâmica (PDT) para o câncer está experimentando um crescimento constante, impulsionado pelo aumento da prevalência do câncer, pela crescente conscientização sobre tratamentos não invasivos e pelos avanços em medicamentos fotossensibilizadores e tecnologias a laser.
Os mercados emergentes estão testemunhando uma rápida adoção da PDT, impulsionada por iniciativas governamentais, aumento dos gastos com saúde e crescimento da população idosa. No entanto, os altos custos do tratamento e o reembolso limitado continuam sendo os principais obstáculos, enquanto as inovações contínuas em terapias combinadas e fotossensibilizadores direcionados apresentam oportunidades significativas de crescimento.
A China deverá dominar o mercado de terapia fotodinâmica (PDT) para o câncer na região Ásia-Pacífico, com a maior participação de receita, de 43,73% em 2025. Esse crescimento é impulsionado por sua grande população de pacientes, pela crescente prevalência de câncer e pelo aumento dos gastos com saúde. O forte apoio governamental a tratamentos avançados contra o câncer, a crescente adoção de terapias inovadoras e a presença de importantes fabricantes nacionais de dispositivos de PDT também contribuem para esse cenário.
Prevê-se que o Japão seja a região de crescimento mais rápido no mercado de terapia fotodinâmica para o câncer na Ásia-Pacífico durante o período de previsão, com uma taxa de crescimento anual composta (CAGR) de 8,9%, impulsionada pelo aumento da prevalência de câncer, uma infraestrutura de saúde altamente avançada e forte apoio governamental a tratamentos inovadores. A crescente conscientização entre pacientes e médicos, juntamente com a adoção de terapias minimamente invasivas, impulsiona a demanda.
O segmento de medicamentos fotossensibilizantes deverá dominar o mercado de terapia fotodinâmica para câncer na região Ásia-Pacífico, com uma participação de mercado de 76,15% em 2025, impulsionado pela crescente adoção da terapia fotodinâmica para diversos tipos de câncer, pelo aumento das aprovações de novos agentes fotossensibilizantes e pela crescente preferência por opções de tratamento minimamente invasivas em toda a região.

Escopo do relatório e segmentação do mercado de terapia fotodinâmica para câncer na região Ásia-Pacífico

Atributos	Principais informações sobre o mercado de seda na região Ásia-Pacífico
Segmentos abrangidos	Por tipo de produto: Medicamentos fotossensibilizantes, dispositivos de terapia fotodinâmica, acessórios e consumíveis. Por indicação de câncer: Oncologia cutânea, Cabeça e pescoço, Esôfago, Pulmão, Bexiga, Colo do útero, Próstata Por modalidade terapêutica: Terapia isolada, Terapia adjuvante, Terapia paliativa, Terapia combinada, Outras Por técnica de procedimento: feixe externo, administração intersticial, administração intracavitária, administração intraoperatória, outras. Por estágio da doença: câncer em estágio inicial, câncer em estágio avançado/metastático Por perfil demográfico do paciente: Pediátrico, Adulto, Geriátrico Por usuário final: Hospitais, Clínicas de Dermatologia e Câncer de Pele, Centros Cirúrgicos Ambulatoriais, Institutos Acadêmicos e de Pesquisa, Outros Por canal de distribuição: Licitações diretas, Distribuidores terceirizados, Online, Outros
Países abrangidos	Ásia-Pacífico China Japão Coréia do Sul Austrália Taiwan Índia Indonésia Hong Kong Nova Zelândia Cingapura Filipinas Tailândia Malásia Resto da Ásia-Pacífico
Principais participantes do mercado	Novartis Pharma AG (Suíça) Galderma SA (Suíça) Bausch Health Companies Inc. (Canadá) Fotocura ASA (Noruega) ADVANZ PHARMA Corp. (Reino Unido) Sun Pharmaceutical Industries Ltd. (Índia) Biofrontera AG (Alemanha) LUMIBIRD SA (França) LUZITIN SA (Portugal) Lumeda Inc. (Suécia) ImPact Biotech (Israel) biolitec Holding GmbH & Co KG (Alemanha) Modulight Corporation (Finlândia) THERALASE TECHNOLOGIES INC.
Oportunidades de mercado	Integração com outras terapias contra o câncer Desenvolvimento de novos fotossensibilizadores
Conjuntos de informações de dados de valor agregado	Além das informações sobre cenários de mercado, como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e principais participantes, os relatórios de mercado elaborados pela Data Bridge Market Research também incluem análise de importação e exportação, visão geral da capacidade de produção, análise de produção e consumo, análise de tendências de preços, cenário de mudanças climáticas, análise da cadeia de suprimentos, análise da cadeia de valor, visão geral de matérias-primas/insumos, critérios de seleção de fornecedores, análise PESTLE, análise de Porter e estrutura regulatória.

Tendências do mercado de terapia fotodinâmica para o câncer na região Ásia-Pacífico

“Integração com outras terapias oncológicas”

A capacidade da terapia fotodinâmica (PDT) de produzir a destruição localizada de células tumorais, ao mesmo tempo que estimula as respostas imunes, posiciona-a como uma parceira atraente para o tratamento multimodal do câncer.
Cada vez mais evidências mostram que a PDT pode aumentar a liberação de antígenos tumorais, modular o microambiente tumoral e aumentar a infiltração ou ativação de células imunes — mecanismos que podem apresentar sinergia com inibidores de checkpoint imunológico, vacinas terapêuticas contra o câncer, quimioterapia ou radioterapia.
A combinação da PDT com terapias sistêmicas pode converter o controle local em respostas sistêmicas duradouras, permitir a redução da dose de agentes tóxicos e expandir as indicações (por exemplo, doença irressecável ou metastática).
Com a multiplicação da pesquisa clínica e translacional, a integração com outras modalidades representa um caminho valioso para ampliar a relevância clínica e a adoção comercial da PDT.

Dinâmica do mercado de terapia fotodinâmica para o câncer na região Ásia-Pacífico

Motorista

“Prevalência crescente do câncer”

O aumento da prevalência do câncer em todo o mundo é um dos principais fatores que impulsionam a demanda por terapias como a terapia fotodinâmica (PDT).
Com o crescimento e envelhecimento da população, e com a melhoria das ferramentas de diagnóstico, mais casos de câncer são detectados a cada ano.
Taxas mais elevadas de fatores de risco, como o uso de tabaco, a obesidade, o sedentarismo, a poluição do ar e as infecções em países de baixa e média renda também contribuem para o aumento da incidência.
Com o aumento do número de pacientes que necessitam de modalidades de tratamento localizadas, eficazes, menos invasivas e com melhor custo-benefício, a PDT torna-se cada vez mais atraente.
O crescente número de casos de câncer sobrecarrega os sistemas de saúde, criando uma pressão urgente por terapias que possam melhorar os resultados, reduzir os efeitos colaterais e ser implementadas de forma mais ampla.

Restrição/Desafio

“Profundidade limitada de penetração da luz”

Uma limitação significativa que dificulta a adoção e a eficácia mais amplas da terapia fotodinâmica é a penetração restrita da luz ativadora nos tecidos humanos.
Como os fotossensibilizadores precisam ser ativados por luz de comprimentos de onda específicos, a absorção e dispersão da luz pelo tecido reduzem a profundidade que a iluminação pode atingir.
Os fotossensibilizadores de luz visível geralmente funcionam apenas para tumores superficiais ou de fácil acesso; tumores mais profundos ou maiores continuam sendo um desafio.
Essa limitação leva à destruição incompleta do tumor, exige a aplicação de luz invasiva (por exemplo, sondas de fibra óptica, endoscopia), aumenta a complexidade do procedimento e pode resultar em desfechos insatisfatórios ou recorrência.
Até que avanços superem essa limitação, a Terapia Fotodinâmica (PDT) permanece restrita ao leque de tipos de câncer que pode tratar de forma não invasiva e eficaz.

Escopo do mercado de terapia fotodinâmica para câncer na região Ásia-Pacífico

O mercado é segmentado com base no tipo de produto, indicação de câncer, modalidade de terapia, técnica de procedimento, estágio da doença, dados demográficos do paciente, usuário final e canal de distribuição.

Por tipo de produto

Com base no tipo de produto, o mercado de terapia fotodinâmica (PDT) para câncer na região Ásia-Pacífico é segmentado em medicamentos fotossensibilizadores e dispositivos de PDT. Em 2025, espera-se que o segmento de medicamentos fotossensibilizadores domine o mercado com 75,38% de participação, devido ao seu papel crucial na eficácia do tratamento, ampla aplicabilidade em diversos tipos de câncer e formulações versáteis (intravenosa, tópica, oral, intravesical e intraperitoneal). Os principais fatores que impulsionam essa dominância incluem a crescente prevalência de câncer, a adoção cada vez maior de terapias minimamente invasivas, as inovações farmacêuticas contínuas e as aprovações regulatórias, que, em conjunto, fazem dos fotossensibilizadores os principais contribuintes para a receita, superando os dispositivos de PDT.

Os medicamentos fotossensibilizadores são o segmento de crescimento mais rápido, com a maior taxa de crescimento anual composta (CAGR) de 6,8% no mercado de terapia fotodinâmica (PDT) para o câncer na região Ásia-Pacífico, devido à crescente adoção de tratamentos oncológicos direcionados e minimamente invasivos. A crescente conscientização sobre a eficácia da PDT, os menores efeitos colaterais em comparação com as terapias convencionais e o desenvolvimento de fotossensibilizadores de última geração com seletividade tumoral aprimorada e penetração tecidual mais profunda estão impulsionando a demanda. Além disso, pesquisas clínicas promissoras e aprovações de novos agentes fotossensibilizantes também contribuem para a expansão do mercado.

Por indicação de câncer

Com base na indicação do câncer, o mercado de terapia fotodinâmica (PDT) para câncer na região Ásia-Pacífico é segmentado em Oncologia Cutânea, Cabeça e Pescoço, Esôfago, Pulmão, Bexiga, Colo do Útero e Próstata. Em 2025, espera-se que o segmento de Oncologia Cutânea domine o mercado com 52,59% de participação, devido à alta prevalência de câncer de pele, à ampla conscientização sobre a detecção precoce e à eficácia da PDT na obtenção de resultados estéticos superiores. O segmento se beneficia da ampla adoção de medicamentos fotossensibilizadores e dispositivos de PDT, especialmente para pacientes geriátricos e adultos, que representam a maior parcela da população. Além disso, a crescente demanda por terapias minimamente invasivas e direcionadas para queratoses actínicas, carcinoma basocelular e carcinoma espinocelular, juntamente com políticas de reembolso favoráveis em regiões-chave, reforça ainda mais sua liderança de mercado em relação a outras indicações de câncer.

O segmento de Oncologia Dermatológica é o que apresenta o crescimento mais rápido, com uma taxa composta de crescimento anual (CAGR) de 7,3% no mercado de terapia fotodinâmica para câncer na região Ásia-Pacífico, devido à crescente prevalência de câncer de pele, à maior conscientização sobre o diagnóstico precoce e à preferência por tratamentos minimamente invasivos com menos efeitos colaterais. A terapia fotodinâmica oferece ação direcionada, recuperação rápida e melhores resultados estéticos, tornando-a altamente favorável para a oncologia dermatológica. Além disso, os avanços tecnológicos em fotossensibilizadores e sistemas de distribuição de luz estão impulsionando a adoção nesse segmento.

Por Modalidade de Terapia

Com base na modalidade terapêutica, o mercado de terapia fotodinâmica (PDT) para câncer na região Ásia-Pacífico é segmentado em terapia isolada, terapia adjuvante, terapia paliativa e outras. Em 2025, espera-se que o segmento de terapia isolada domine o mercado com 41,67% de participação, devido à sua eficácia como tratamento primário para cânceres localizados, incluindo câncer de pele, esôfago e pulmão. Os principais fatores que impulsionam essa dominância incluem alta eficácia, mínima invasividade, resultados estéticos superiores e crescente preferência clínica por terapias direcionadas. Regionalmente, a Ásia-Pacífico lidera a adoção da PDT isolada devido à infraestrutura de saúde avançada, estruturas de reembolso estabelecidas e alta conscientização dos pacientes, enquanto os mercados emergentes na Ásia-Pacífico estão testemunhando uma crescente adoção impulsionada pela crescente prevalência de câncer, expansão das redes hospitalares e maior acesso a tratamentos oncológicos modernos. Essas dinâmicas regionais, combinadas com o aumento da educação e da conscientização sobre os benefícios da PDT, reforçam a dominância da terapia isolada globalmente.

A terapia isolada é o segmento de crescimento mais rápido, com uma taxa de crescimento anual composta (CAGR) de 7,2% no mercado de terapia fotodinâmica para câncer na região Ásia-Pacífico, devido à sua simplicidade, custo-benefício e redução dos efeitos colaterais em comparação com as terapias combinadas. Ela permite o tratamento direcionado do tumor sem a necessidade de medicamentos ou intervenções adicionais, melhorando a adesão do paciente. A crescente adoção em ambientes ambulatoriais, a maior conscientização sobre tratamentos minimamente invasivos e os avanços em fotossensibilizadores e sistemas de distribuição de luz estão impulsionando ainda mais o rápido crescimento desse segmento.

Por meio da técnica de procedimento

Com base na técnica de procedimento, o mercado de terapia fotodinâmica para câncer na região Ásia-Pacífico é segmentado em feixe externo, administração intracavitária (endoscópica), administração intersticial (interna) e outras. Em 2025, espera-se que o segmento de feixe externo domine o mercado com 69,22% de participação, devido à sua natureza não invasiva, facilidade de uso e eficácia para tumores superficiais. A forte adoção, impulsionada por infraestrutura de saúde avançada e políticas de reembolso, juntamente com a crescente demanda na região Ásia-Pacífico devido à maior prevalência e conscientização sobre o câncer, sustenta sua liderança de mercado.

O segmento de administração intracavitária (endoscópica) é o que apresenta o crescimento mais rápido, com uma taxa de crescimento anual composta (CAGR) de 8,8% no mercado de terapia fotodinâmica para câncer na região Ásia-Pacífico, devido à crescente adoção de procedimentos minimamente invasivos, à prevalência crescente de cânceres gastrointestinais e torácicos, aos avanços tecnológicos em equipamentos endoscópicos e à crescente preferência por abordagens de tratamento direcionadas e localizadas que reduzem os efeitos colaterais sistêmicos.

Por estágio da doença

Com base no estágio da doença, o mercado de terapia fotodinâmica (PDT) para câncer na região Ásia-Pacífico é segmentado em câncer em estágio inicial e câncer em estágio avançado. Em 2025, espera-se que o segmento de câncer em estágio inicial domine o mercado com 81,65% de participação, devido à eficácia da PDT em atingir tumores localizados, minimizar danos ao tecido saudável e oferecer melhores resultados estéticos. O segmento se beneficia da alta conscientização dos pacientes, da preferência por tratamentos minimamente invasivos e da ampla adoção na região Ásia-Pacífico, enquanto o aumento das taxas de diagnóstico de câncer e a expansão da infraestrutura oncológica reforçam ainda mais sua liderança de mercado.

O câncer em estágio inicial é o segmento de crescimento mais rápido, com uma taxa de crescimento anual composta (CAGR) de 6,8% no mercado de terapia fotodinâmica (PDT) para câncer na região Ásia-Pacífico, devido à crescente adoção de tratamentos minimamente invasivos, à maior conscientização sobre a detecção precoce e aos melhores resultados para os pacientes com a PDT. Os cânceres em estágio inicial respondem melhor às terapias direcionadas, resultando em maior eficácia e menos efeitos colaterais. Além disso, iniciativas governamentais de apoio e avanços em fotossensibilizadores e sistemas de distribuição de luz estão impulsionando uma penetração de mercado mais rápida nesse segmento.

Por dados demográficos do paciente

Com base nos dados demográficos dos pacientes, o mercado de terapia fotodinâmica para câncer na região Ásia-Pacífico é segmentado em geriátrico, adulto e pediátrico. Em 2025, espera-se que o segmento geriátrico domine o mercado com 67,74% de participação, devido à maior prevalência de câncer entre idosos, à maior suscetibilidade a cânceres de pele e cutâneos e à preferência por tratamentos minimamente invasivos e direcionados. A forte adoção na América do Norte e na região Ásia-Pacífico é impulsionada por infraestrutura de saúde avançada e conscientização, juntamente com o crescimento da população idosa.

O segmento geriátrico é o que apresenta o crescimento mais rápido, com uma taxa de crescimento anual composta (CAGR) de 6,9% no mercado de terapia fotodinâmica (PDT) para o câncer na região Ásia-Pacífico, devido à maior prevalência de câncer entre os idosos. O envelhecimento enfraquece o sistema imunológico e aumenta a suscetibilidade a vários tipos de câncer, impulsionando a demanda por tratamentos eficazes e minimamente invasivos, como a PDT. Além disso, a PDT oferece menos efeitos colaterais e recuperação mais rápida, tornando-a adequada para pacientes idosos que podem não tolerar terapias agressivas, o que impulsiona o crescimento do mercado nessa faixa etária.

Por usuário final

Com base no usuário final, o mercado de terapia fotodinâmica (PDT) para câncer na região Ásia-Pacífico é segmentado em hospitais, clínicas de dermatologia e câncer de pele, centros cirúrgicos ambulatoriais (CCAs), instituições acadêmicas e de pesquisa e outros. Em 2025, espera-se que o segmento de hospitais domine o mercado com 41,80% de participação, devido à sua infraestrutura abrangente, disponibilidade de departamentos de oncologia especializados e capacidade de oferecer tratamentos integrados de PDT. Hospitais públicos e privados, principalmente os de nível 1 e 2 na América do Norte e na região Ásia-Pacífico, lideram a adoção da terapia devido aos seus sistemas de saúde avançados e suporte de reembolso. A expansão das redes hospitalares e dos serviços de oncologia reforça ainda mais a dominância dos hospitais como os principais usuários finais da PDT para câncer em todo o mundo.

Os hospitais são o segmento de crescimento mais rápido, com uma taxa de crescimento anual composta (CAGR) de 7,5% no mercado de terapia fotodinâmica (PDT) para o câncer na região Ásia-Pacífico, devido à crescente adoção de tratamentos oncológicos avançados, ao maior fluxo de pacientes e à disponibilidade de departamentos de oncologia especializados. Os hospitais oferecem serviços abrangentes de PDT, incluindo diagnóstico, tratamento e cuidados pós-terapia, o que os torna preferíveis a clínicas independentes. Além disso, a crescente conscientização, as iniciativas governamentais e a cobertura de planos de saúde impulsionam ainda mais a adoção da PDT em hospitais.

Por canal de distribuição

Com base no canal de distribuição, o mercado de terapia fotodinâmica (PDT) para câncer na região Ásia-Pacífico é segmentado em Licitação Direta, Distribuidores Terceirizados, Online e Outros. Em 2025, espera-se que o segmento de Licitação Direta domine o mercado com 51,18% de participação, devido à aquisição em grande escala por hospitais, programas governamentais de saúde e grandes centros de oncologia, o que garante custo-benefício e fornecimento confiável de fotossensibilizadores e equipamentos de PDT. A forte adoção na América do Norte e na região Ásia-Pacífico é impulsionada por sistemas estruturados de aquisição hospitalar e licitações públicas de saúde, juntamente com a crescente demanda institucional.

O segmento de Licitação Direta é o que apresenta o crescimento mais rápido, com uma taxa composta de crescimento anual (CAGR) de 7,0% no mercado de Terapia Fotodinâmica (PDT) para o câncer na região Ásia-Pacífico, devido ao aumento das aquisições de equipamentos avançados de PDT por governos e hospitais por meio de contratos diretos. Essa abordagem garante custo-benefício, aquisição mais rápida e fornecimento confiável para programas de tratamento de câncer em larga escala. Além disso, o aumento dos gastos públicos com saúde, as iniciativas governamentais para o tratamento do câncer e a preferência por compras centralizadas impulsionam a adoção da licitação direta em detrimento de distribuidores ou canais online.

Análise Regional do Mercado de Terapia Fotodinâmica para o Câncer na Ásia-Pacífico

A China deverá dominar o mercado de terapia fotodinâmica (PDT) para o câncer na região Ásia-Pacífico, com a maior participação de receita, de 43,73% em 2025. Esse crescimento é impulsionado por sua grande população de pacientes, pela crescente prevalência de câncer e pelo aumento dos gastos com saúde. Além disso, o forte apoio governamental a tratamentos avançados contra o câncer, a crescente adoção de terapias inovadoras e a presença de importantes fabricantes nacionais de dispositivos de PDT também contribuem para esse cenário.
Prevê-se que o Japão seja a região de crescimento mais rápido no mercado de terapia fotodinâmica para o câncer na Ásia-Pacífico durante o período de previsão, com uma taxa de crescimento anual composta (CAGR) de 8,9%, impulsionada pelo aumento da prevalência de câncer, uma infraestrutura de saúde altamente avançada e forte apoio governamental a tratamentos inovadores. A crescente conscientização entre pacientes e médicos, juntamente com a adoção de terapias minimamente invasivas, impulsiona a demanda.
Além disso, a expansão da infraestrutura de saúde e o aumento da conscientização entre pacientes e médicos.

Análise do Mercado de Terapia Fotodinâmica para Câncer na Austrália e na Região Ásia-Pacífico

O mercado de terapia fotodinâmica (PDT) para o câncer na região Ásia-Pacífico, incluindo a Austrália, desempenha um papel significativo no cenário de tratamento do câncer na região, impulsionado por sua infraestrutura de saúde avançada, forte ecossistema de pesquisa oncológica e disponibilidade de centros especializados em câncer. A alta adoção de terapias inovadoras e minimamente invasivas, as iniciativas governamentais de apoio ao tratamento do câncer e a crescente incidência de câncer de pele impulsionam o crescimento do mercado. Além disso, as colaborações entre instituições de pesquisa australianas, universidades e empresas farmacêuticas globais aceleram o desenvolvimento e a comercialização da PDT, posicionando a Austrália como um importante contribuinte para o mercado da Ásia-Pacífico.

Análise do Mercado de Terapia Fotodinâmica para Câncer na Coreia do Sul e na Região Ásia-Pacífico

O mercado de terapia fotodinâmica (PDT) para o câncer na Coreia do Sul, região Ásia-Pacífico, deverá crescer de forma constante, impulsionado por um sistema de saúde consolidado, pela rápida adoção de tecnologias avançadas para o tratamento do câncer e por fortes iniciativas governamentais para aprimorar o atendimento oncológico. A crescente prevalência de cânceres como o gástrico, hepático e pulmonar, juntamente com a maior conscientização sobre terapias minimamente invasivas como a PDT, está impulsionando a demanda. Regimes de reembolso favoráveis, investimentos em pesquisa e desenvolvimento (P&D) e colaborações entre hospitais, universidades e empresas biofarmacêuticas globais aceleram ainda mais a penetração no mercado e o crescimento sustentado no país.

Os principais líderes de mercado que atuam no setor são:

Novartis Pharma AG (Suíça)
Galderma SA (Suíça)
Bausch Health Companies Inc. (Canadá)
Fotocura ASA (Noruega)
ADVANZ PHARMA Corp. (Reino Unido)
Sun Pharmaceutical Industries Ltd. (Índia)
Biofrontera AG (Alemanha)
LUMIBIRD SA (França)
LUZITIN SA (Portugal)
Lumeda Inc. (Suécia)
ImPact Biotech (Israel)
biolitec Holding GmbH & Co KG (Alemanha)
Modulight Corporation (Finlândia)

THERALASE TECHNOLOGIES INC.

Últimos desenvolvimentos no mercado de terapia fotodinâmica para o câncer na região Ásia-Pacífico

Em fevereiro de 2023, a colaboração entre a Galderma e a German Medical Engineering (GME) representa um desenvolvimento estratégico no mercado de dermatologia e terapia fotodinâmica (PDT). Ao combinar o Metvix da Galderma, um fotossensibilizador líder para lesões pré-cancerosas e cânceres de pele não melanoma, com o dispositivo MultiLite da GME, a parceria fortalece a oferta de tratamentos integrados da Galderma e expande sua capacidade de fornecer tanto a PDT convencional com luz vermelha (C-PDT) quanto a PDT com luz artificial diurna (ADL-PDT), mais confortável para o paciente.
Em 2025, a McKesson concluiu a aquisição da Core Ventures (Community Oncology Revitalization Enterprise Ventures), adquirindo uma participação majoritária de aproximadamente 70% por cerca de US$ 2,49 bilhões, para fortalecer seu atendimento oncológico comunitário por meio do Florida Cancer Specialists & Research Institute.
Em 2025, a Biofrontera AG transferiu todos os ativos nos EUA relacionados ao Ameluz e ao RhodoLED para a Biofrontera Inc., recebendo uma participação acionária de 10% e royalties de 12 a 15% sobre as vendas do Ameluz nos EUA.

SKU-74824

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Click on image to enlarge

Painel interativo de análise de dados
Painel de análise da empresa para oportunidades de elevado potencial de crescimento
Acesso de analista de pesquisa para personalização e customização. consultas
Análise da concorrência com painel interativo
Últimas notícias, atualizações e atualizações Análise de tendências
Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência

Pedido de demonstração

Índice

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 MARKET END USER COVERAGE GRID

2.1 SECONDARY SOURCES

2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 PRODUCTION CONSUMPTION ANALYSIS

4.3.1 INTRODUCTION

4.3.2 PRODUCTION SIDE ANALYSIS

4.3.2.1 PHOTOSENSITIZER MANUFACTURING

4.3.2.2 DEVICE MANUFACTURING

4.3.2.3 RESEARCH AND INNOVATION

4.3.3 CONSUMPTION SIDE ANALYSIS

4.3.3.1 CLINICAL APPLICATION

4.3.3.2 TREATMENT VOLUMES AND TRENDS

4.3.3.3 DOSAGE AND PROTOCOLS

4.3.4 PRODUCTION–CONSUMPTION DYNAMICS

4.3.4.1 SUPPLY CONSTRAINTS

4.3.4.2 REGIONAL OVERVIEW

4.3.4.3 FUTURE OUTLOOK

4.3.5 CONCLUSION

4.4 COST ANALYSIS BREAKDOWN

4.4.1 INTRODUCTION

4.4.2 DIRECT MEDICAL COSTS

4.4.2.1 COST OF PHOTOSENSITIZERS

4.4.2.2 LIGHT DELIVERY SYSTEMS

4.4.2.3 HEALTHCARE FACILITY CHARGES

4.4.3 INDIRECT COSTS

4.4.3.1 PATIENT-RELATED EXPENSES

4.4.3.2 POST-TREATMENT MONITORING

4.4.4 COMPARATIVE COST-EFFECTIVENESS

4.4.5 REIMBURSEMENT AND INSURANCE IMPACT

4.4.6 REGIONAL COST VARIATIONS

4.4.7 FUTURE COST TRENDS AND REDUCTION STRATEGIES

4.4.7.1 TECHNOLOGICAL ADVANCEMENTS

4.4.7.2 HEALTHCARE EFFICIENCY INITIATIVES

4.4.8 CONCLUSION

4.5 TECHNOLOGICAL ADVANCEMENTS

4.5.1 INTRODUCTION

4.5.2 NEXT-GENERATION PHOTOSENSITIZERS

4.5.3 ADVANCEMENTS IN LIGHT DELIVERY SYSTEMS

4.5.4 NANOTECHNOLOGY-ENABLED DELIVERY

4.5.5 COMBINATION THERAPIES AND IMMUNOMODULATION

4.5.6 DIGITAL INTEGRATION AND TREATMENT PLANNING

4.5.7 RECENT TRENDS AND OUTLOOK

4.5.8 CONCLUSION

4.6 VALUE CHAIN ANALYSIS

4.6.1 INTRODUCTION

4.6.2 RESEARCH & DEVELOPMENT

4.6.2.1 DISCOVERY OF PHOTOSENSITIZERS

4.6.2.2 DEVELOPMENT OF LIGHT DELIVERY SYSTEMS

4.6.2.3 CLINICAL TRIALS AND REGULATORY APPROVALS

4.6.3 MANUFACTURING

4.6.3.1 PRODUCTION OF PHOTOSENSITIZERS

4.6.3.2 FABRICATION OF LIGHT DELIVERY DEVICES

4.6.4 DISTRIBUTION & LOGISTICS

4.6.4.1 SUPPLY CHAIN MANAGEMENT

4.6.4.2 INTERNATIONAL TRADE AND MARKET ACCESS

4.6.5 CLINICAL APPLICATION

4.6.5.1 INTEGRATION INTO TREATMENT PROTOCOLS

4.6.5.2 TRAINING AND EDUCATION

4.6.6 POST-TREATMENT MONITORING & SUPPORT

4.6.6.1 FOLLOW-UP CARE

4.6.6.2 PATIENT SUPPORT SERVICES

4.6.7 TECHNOLOGICAL ADVANCEMENTS INFLUENCING THE PDT VALUE CHAIN

4.6.7.1 NANOTECHNOLOGY IN PDT

4.6.7.2 ARTIFICIAL INTELLIGENCE AND IMAGING

4.6.7.3 PERSONALIZED MEDICINE

4.6.8 CONCLUSION

4.7 VENDOR SELECTION CRITERIA

4.7.1 INTRODUCTION

4.7.2 CORE SELECTION CRITERIA

4.7.2.1 REGULATORY COMPLIANCE

4.7.2.2 CLINICAL EVIDENCE AND RESEARCH SUPPORT

4.7.2.3 TECHNICAL PERFORMANCE AND DEVICE COMPATIBILITY

4.7.2.4 QUALITY MANAGEMENT AND MANUFACTURING STANDARDS

4.7.2.5 SERVICE, TRAINING, AND AFTER-SALES SUPPORT

4.7.2.6 SUPPLY CHAIN RELIABILITY

4.7.3 RECENT TRENDS IN VENDOR SELECTION

4.7.4 RISK FACTORS AND VULNERABILITIES

4.7.5 KEY PERFORMANCE INDICATORS

4.7.6 STRATEGIC RECOMMENDATIONS

4.7.7 CONCLUSION

4.8 PATENT ANALYSIS

4.8.1 PATENT QUALITY AND STRENGTH

4.8.2 PATENT FAMILIES

4.8.3 LICENSING AND COLLABORATIONS

4.8.4 REGIONAL PATENT LANDSCAPE

4.8.5 IP STRATEGY AND MANAGEMENT

4.9 SUPPLY CHAIN ANALYSIS

4.9.1 OVERVIEW

4.9.2 LOGISTIC COST SCENARIO

4.9.3 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS

4.9.4 CONCLUSION

4.1 INDUSTRY ECOSYSTEM ANALYSIS

4.10.1 INTRODUCTION

4.10.2 ECOSYSTEM ARCHITECTURE — KEY ACTORS AND ROLES

4.10.2.1 CORE TECHNOLOGY PROVIDERS

4.10.2.2 ENABLING INSTITUTIONS

4.10.3 VALUE CHAIN AND FUNCTIONAL FLOWS

4.10.3.1 RESEARCH AND DISCOVERY

4.10.3.2 CLINICAL DEVELOPMENT AND REGULATORY VALIDATION

4.10.3.3 MANUFACTURING AND QUALITY ASSURANCE

4.10.3.4 DISTRIBUTION, PROCUREMENT AND CLINICAL ADOPTION

4.10.4 MARKET ENABLERS AND INFRASTRUCTURE

4.10.4.1 SCIENTIFIC AND REGULATORY ENABLERS

4.10.4.2 REIMBURSEMENT AND HEALTH-ECONOMICS INFRASTRUCTURE

4.10.4.3 MANUFACTURING AND SUPPLY-CHAIN CAPACITY

4.10.5 INTERDEPENDENCIES AND STRATEGIC PARTNERSHIPS

4.10.5.1 ACADEMIA-INDUSTRY TECHNOLOGY TRANSFER

4.10.5.2 VERTICAL INTEGRATION AND CONTRACT MANUFACTURING

4.10.5.3 CLINICAL NETWORKS AND KOL ECOSYSTEMS

4.10.6 RISKS, CONSTRAINTS AND SYSTEMIC VULNERABILITIES

4.10.6.1 REGULATORY COMPLEXITY FOR COMBINED PRODUCTS

4.10.6.2 SUPPLY-CHAIN CONCENTRATION AND MATERIAL RISK

4.10.6.3 EVIDENCE AND REIMBURSEMENT UNCERTAINTY

4.10.6.4 CLINICAL OPERATIONAL BARRIERS

4.10.7 STRATEGIC IMPLICATIONS AND RECOMMENDATIONS

4.10.8 OUTLOOK — EVOLUTION OF THE ECOSYSTEM

4.10.9 CONCLUSION

4.11 INNOVATION TRACKER AND STRATEGIC ANALYSIS

4.11.1 INTRODUCTION

4.11.2 RECENT TECHNOLOGICAL INNOVATIONS

4.11.2.1 ADVANCED PHOTOSENSITIZERS

4.11.2.2 OXYGEN-SELF-SUFFICIENT PLATFORMS

4.11.2.3 ALTERNATIVE ACTIVATION MODALITIES

4.11.2.4 SMART NANOPLATFORMS

4.11.2.5 NOVEL CHEMICAL STRUCTURES

4.11.3 STRATEGIC INNOVATIONS IN DELIVERY SYSTEMS

4.11.3.1 LIGHT DELIVERY DEVICES

4.11.3.2 COMBINATION THERAPIES

4.11.3.3 IMAGING INTEGRATION

4.11.4 KEY CHALLENGES

4.11.5 STRATEGIC THEMES

4.11.6 STRATEGIC IMPLICATIONS FOR MARKET PLAYERS

4.11.7 RECOMMENDATIONS

4.11.8 OUTLOOK AND STRATEGIC RISKS

4.11.9 CONCLUSION

4.12 PRICING ANALYSIS

4.12.1 INTRODUCTION

4.12.2 COMPONENTS OF THE TOTAL TREATMENT PRICE

4.12.2.1 PHOTOSENSITIZING AGENT (DRUG) COSTS

4.12.2.2 DEVICE CAPITAL AND MAINTENANCE COST

4.12.2.3 CONSUMABLES AND PROCEDURAL OVERHEAD

4.12.2.4 INDIRECT AND DOWNSTREAM COSTS

4.12.3 PRICING MODELS AND APPROACHES

4.12.3.1 COST-PLUS AND MARKUP MODELS

4.12.3.2 VALUE-BASED AND OUTCOMES-LINKED PRICING

4.12.3.3 BUNDLED PAYMENTS AND PROCEDURAL TARIFFS

4.12.3.4 SUBSCRIPTION AND MANAGED-SERVICE MODELS FOR DEVICES

4.12.4 REIMBURSEMENT LANDSCAPE

4.12.4.1 UNITED STATES: MEDICARE AND COMMERCIAL PAYERS

4.12.4.2 EUROPE AND OTHER HIGH-INCOME MARKETS

4.12.4.3 EMERGING MARKETS AND OUT-OF-POCKET DYNAMICS

4.12.5 REGIONAL PRICE DIFFERENTIALS AND DRIVERS

4.12.5.1 MANUFACTURING FOOTPRINT AND SUPPLY-CHAIN EFFECTS

4.12.5.2 REGULATORY BURDEN AND MARKET ACCESS TIMELINES

4.12.5.3 CLINICAL PRACTICE PATTERNS AND REIMBURSEMENT POLICY

4.12.6 PRICE SENSITIVITY, ACCESS, AND EQUITY

4.12.6.1 PRICE ELASTICITY IN HOSPITAL PROCUREMENT

4.12.6.2 PATIENT ACCESS AND SOCIOECONOMIC BARRIERS

4.12.7 COMPETITIVE & STRATEGIC PRICING IMPLICATIONS

4.12.7.1 DIFFERENTIATION-BASED PREMIUM PRICING

4.12.7.2 PENETRATION PRICING AND VOLUME STRATEGIES

4.12.7.3 MANAGED ENTRY AGREEMENTS AND OUTCOMES GUARANTEES

4.12.8 RECOMMENDATIONS FOR STAKEHOLDERS

4.12.8.1 FOR MANUFACTURERS

4.12.8.2 FOR PROVIDERS AND HOSPITAL SYSTEMS

4.12.8.3 FOR PAYERS AND POLICYMAKERS

4.12.9 RISKS, UNCERTAINTIES, AND FUTURE PRICE PRESSURES

4.12.10 CONCLUSION

5 TARIFFS & IMPACT ON THE MARKET

5.1 INTRODUCTION

5.2 TARIFF LANDSCAPE RELEVANT TO PDT PRODUCTS

5.2.1 CATEGORIES OF TRADE EXPOSURE

5.2.2 RECENT AND EMERGING TARIFF MEASURES OF CONSEQUENCE

5.3 DIRECT COST IMPACTS

5.3.1 INCREASED LANDED COSTS AND MARGIN COMPRESSION

5.3.2 PRICE VOLATILITY AND PROCUREMENT BUDGETING

5.4 SUPPLY-CHAIN & MANUFACTURING IMPLICATIONS

5.4.1 SUPPLIER DIVERSIFICATION AND RESHORING INCENTIVES

5.4.2 SOURCING OF HIGH-VALUE NANOMATERIALS AND COMPONENTS

5.4.3 REGULATORY AND QUALIFICATION COSTS FOR NEW SUPPLIERS

5.5 CLINICAL ACCESS, PRICING & REIMBURSEMENT EFFECTS

5.5.1 ACCESS RISK FOR PATIENTS AND PROVIDERS

5.5.2 REIMBURSEMENT PRESSURE AND HEALTH-ECONOMIC ASSESSMENTS

5.6 R&D, INNOVATION & COMPETITIVE IMPLICATIONS

5.6.1 DISRUPTION OF RESEARCH SUPPLIES AND COLLABORATION FLOWS

5.6.2 STRATEGIC REPOSITIONING AND COMPETITIVE ADVANTAGE

5.7 POLICY, COMPLIANCE & REGULATORY CONSIDERATIONS

5.7.1 USE OF WTO AND PREFERENTIAL TRADE RULES

5.7.2 TARIFF MITIGATION TOOLS AND ADVOCACY

5.8 RECOMMENDATIONS FOR STAKEHOLDERS

5.9 CONCLUSION

6 REGULATION COVERAGE

6.1 PRODUCT CODES

6.1.1 CERTIFIED STANDARDS

6.1.2 SAFETY STANDARDS

6.1.3 MATERIAL HANDLING & STORAGE

6.1.4 TRANSPORT & PRECAUTIONS

6.1.5 HAZARD IDENTIFICATION

6.1.6 CONCLUSION

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE OF CANCER

7.1.2 GROWING PREFERENCE FOR MINIMALLY INVASIVE THERAPIES

7.1.3 TECHNOLOGICAL ADVANCEMENTS IN PHOTOSENSITIZERS AND DEVICES

7.1.4 EXPANDING RESEARCH AND CLINICAL DEVELOPMENT PIPELINE

7.2 RESTRAINTS

7.2.1 LIMITED DEPTH OF LIGHT PENETRATION

7.2.2 HIGH COST OF TREATMENT

7.3 OPPORTUNITIES

7.3.1 INTEGRATION WITH OTHER CANCER THERAPIES

7.3.2 DEVELOPMENT OF NOVEL PHOTOSENSITIZERS

7.3.3 M&A AND PARTNERSHIPS WITH ONCOLOGY DEVICE/LASER FIRMS AND PHARMA

7.4 CHALLENGES

7.4.1 TUMOR HYPOXIA AS A BIOLOGICAL BARRIER TO PHOTODYNAMIC THERAPY EFFICACY

7.4.2 COMPETITION FROM ALTERNATIVE TREATMENTS

8 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE

8.1 OVERVIEW

8.2 PHOTOSENSITIZER DRUGS

8.3 PHOTODYNAMIC THERAPY DEVICES

9 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION

9.1 OVERVIEW

9.2 SKIN & CUTANEOUS ONCOLOGY

9.3 HEAD & NECK

9.4 ESOPHAGAL

9.5 LUNG

9.6 BLADDER

9.7 CERVICAL

9.8 PROSTATE

10 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY

10.1 OVERVIEW

10.2 STANDALONE THERAPY

10.3 ADJUNCTIVE THERAPY

10.4 PALLIATION THERAPY

10.5 OTHERS

11 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE

11.1 OVERVIEW

11.2 EXTERNAL BEAM

11.3 INTRACAVITARY (ENDOSCOPIC) DELIVERY

11.4 INTERSTITIAL (INTERNAL) DELIVERY

11.5 OTHERS

12 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE

12.1 OVERVIEW

12.2 EARLY-STAGE CANCER

12.3 LATE-STAGE CANCER

13 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS

13.1 OVERVIEW

13.2 GERIATRIC

13.3 ADULTS

13.4 PEDIATRIC

14 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 DERMATOLOGY & SKIN-CANCER CLINICS

14.4 AMBULATORY SURGICAL CENTERS (ASCS)

14.5 ACADEMIC & RESEARCH INSTITUTES

14.6 OTHERS

15 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT TENDER

15.3 THIRD PARTY DISTRIBUTORS

15.4 ONLINE

15.5 OTHERS

16 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION

16.1 ASIA-PACIFIC

16.1.1 CHINA

16.1.2 JAPAN

16.1.3 SOUTH KOREA

16.1.4 AUSTRAILA

16.1.5 TAIWAN

16.1.6 INDIA

16.1.7 INDONESIA

16.1.8 HONG KONG

16.1.9 NEW ZEALAND

16.1.10 SINGAPORE

16.1.11 PHILIPPINES

16.1.12 THAILAND

16.1.13 MALAYSIA

16.1.14 REST OF ASIA-PACIFIC

17 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET : COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: GLOBAL

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 NOVERTIS AG

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENT

19.2 GALDERMA S. A.

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENTS

19.3 PHOTOCURE

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENT

19.4 ADVANZ PHARMA CORP.

19.4.1 COMPANY SNAPSHOT

19.4.2 COMPANY SHARE ANALYSIS

19.4.3 PRODUCT PORTFOLIO

19.4.4 RECENT DEVELOPMENT

19.5 AMERISOURCE BERGEN CORPORATION

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENT

19.6 BIOFRONTERA AG

19.6.1 COMPANY SNAPSHOT

19.6.2 REVENUE ANALYSIS

19.6.3 PRODUCT PORTFOLIO

19.6.4 RECENT DEVELOPMENTS

19.7 BIOLITEC HOLDING GMBH & CO KG

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 CARDINAL HEALTH

19.8.1 COMPANY SNAPSHOT

19.8.2 REVENUE ANALYSIS

19.8.3 PRODUCT PORTFOLIO

19.8.4 RECENT DEVELOPMENT

19.9 HEMERION THERAPEUTICS

19.9.1 COMPANY SNAPSHOT

19.9.2 PRODUCT PORTFOLIO

19.9.3 RECENT DEVELOPMENTS

19.1 IMPACT BIOTECH

19.10.1 COMPANY SNAPSHOT

19.10.2 PRODUCT PORTFOLIO

19.10.3 RECENT DEVELOPMENTS

19.11 INOVA

19.11.1 COMPANY SNAPSHOT

19.11.2 PRODUCT PORTFOLIO

19.11.3 RECENT DEVELOPMENT

19.12 LUMIBIRD

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENT

19.13 LUZITIN

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENT

19.14 MCKESSON

19.14.1 COMPANY SNAPSHOT

19.14.2 REVENUE ANALYSIS

19.14.3 PRODUCT PORTFOLIO

19.14.4 RECENT DEVELOPMENTS

19.15 MODULIGHT CORPORATION

19.15.1 COMPANY SNAPSHOT

19.15.2 REVENUE ANALYSIS

19.15.3 PRODUCT PORTFOLIO

19.15.4 RECENT DEVELOPMENT

19.16 ONCOLUX INC (FORMERLY LUMEDA INC.)

19.16.1 COMPANY SNAPSHOT

19.16.2 PRODUCT PORTFOLIO

19.16.3 RECENT DEVELOPMENT

19.17 SUN PHARMACEUTICAL INDUSTRIES LTD

19.17.1 COMPANY SNAPSHOT

19.17.2 REVENUE ANALYSIS

19.17.3 PRODUCT PORTFOLIO

19.17.4 RECENT DEVELOPMENT

19.18 THERALASE TECHNOLOGIES INC.

19.18.1 COMPANY SNAPSHOT

19.18.2 REVENUSE ANALYSIS

19.18.3 PRODUCT PORTFOLIO

19.18.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

Lista de Tabela

TABLE 1 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 2 ASIA-PACIFIC PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 3 ASIA-PACIFIC PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 4 ASIA-PACIFIC PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 5 ASIA-PACIFIC PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 6 ASIA-PACIFIC PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 7 ASIA-PACIFIC LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 8 ASIA-PACIFIC ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 9 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 10 ASIA-PACIFIC SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 11 ASIA-PACIFIC SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 12 ASIA-PACIFIC SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 13 ASIA-PACIFIC HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 14 ASIA-PACIFIC HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 15 ASIA-PACIFIC HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 16 ASIA-PACIFIC ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 17 ASIA-PACIFIC ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 18 ASIA-PACIFIC ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 19 ASIA-PACIFIC LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 20 ASIA-PACIFIC LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 21 ASIA-PACIFIC LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 22 ASIA-PACIFIC BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 23 ASIA-PACIFIC BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 24 ASIA-PACIFIC BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 25 ASIA-PACIFIC CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 26 ASIA-PACIFIC CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 27 ASIA-PACIFIC CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 28 ASIA-PACIFIC PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 29 ASIA-PACIFIC PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 30 ASIA-PACIFIC PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 31 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 32 ASIA-PACIFIC STANDALONE THERAPY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 33 ASIA-PACIFIC ADJUNCTIVE THERAPY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 34 ASIA-PACIFIC PALLIATION THERAPY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 35 ASIA-PACIFIC OTHERS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 36 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 37 ASIA-PACIFIC EXTERNAL BEAM IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 38 ASIA-PACIFIC INTRACAVITARY (ENDOSCOPIC) DELIVERY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 39 ASIA-PACIFIC INTERSTITIAL (INTERNAL) DELIVERY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 40 ASIA-PACIFIC OTHERS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 41 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 42 ASIA-PACIFIC EARLY-STAGE CANCER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 43 ASIA-PACIFIC LATE-STAGE CANCER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 44 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 45 ASIA-PACIFIC GERIATRIC IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 46 ASIA-PACIFIC ADULTS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 47 ASIA-PACIFIC PEDIATRIC IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 48 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 49 ASIA-PACIFIC HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 50 ASIA-PACIFIC HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 51 ASIA-PACIFIC HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 52 ASIA-PACIFIC DERMATOLOGY & SKIN-CANCER CLINICS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 53 ASIA-PACIFIC AMBULATORY SURGICAL CENTERS (ASCS) IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 54 ASIA-PACIFIC ACADEMIC & RESEARCH INSTITUTES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 55 ASIA-PACIFIC OTHERS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 56 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 57 ASIA-PACIFIC DIRECT TENDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 58 ASIA-PACIFIC THIRD PARTY DISTRIBUTORS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 59 ASIA-PACIFIC ONLINE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 60 ASIA-PACIFIC OTHERS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 61 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 62 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 63 ASIA-PACIFIC PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 64 ASIA-PACIFIC PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 65 ASIA-PACIFIC PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 66 ASIA-PACIFIC LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 67 ASIA-PACIFIC ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 68 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 69 ASIA-PACIFIC SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 70 ASIA-PACIFIC SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 71 ASIA-PACIFIC HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 72 ASIA-PACIFIC HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 73 ASIA-PACIFIC ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 74 ASIA-PACIFIC ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 75 ASIA-PACIFIC LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 76 ASIA-PACIFIC LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 77 ASIA-PACIFIC BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 78 ASIA-PACIFIC BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 79 ASIA-PACIFIC CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 80 ASIA-PACIFIC CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 81 ASIA-PACIFIC PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 82 ASIA-PACIFIC PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 83 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 84 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 85 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 86 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 87 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 88 ASIA-PACIFIC HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 89 ASIA-PACIFIC HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 90 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 91 CHINA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 92 CHINA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 93 CHINA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 94 CHINA PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 95 CHINA LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 96 CHINA ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 97 CHINA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 98 CHINA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 99 CHINA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 100 CHINA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 101 CHINA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 102 CHINA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 103 CHINA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 104 CHINA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 105 CHINA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 106 CHINA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 107 CHINA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 108 CHINA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 109 CHINA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 110 CHINA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 111 CHINA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 112 CHINA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 113 CHINA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 114 CHINA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 115 CHINA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 116 CHINA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 117 CHINA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 118 CHINA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 119 CHINA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 120 JAPAN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 121 JAPAN PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 122 JAPAN PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 123 JAPAN PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 124 JAPAN LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 125 JAPAN ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 126 JAPAN CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 127 JAPAN SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 128 JAPAN SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 129 JAPAN HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 130 JAPAN HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 131 JAPAN ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 132 JAPAN ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 133 JAPAN LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 134 JAPAN LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 135 JAPAN BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 136 JAPAN BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 137 JAPAN CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 138 JAPAN CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 139 JAPAN PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 140 JAPAN PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 141 JAPAN CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 142 JAPAN CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 143 JAPAN CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 144 JAPAN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 145 JAPAN CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 146 JAPAN HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 147 JAPAN HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 148 JAPAN CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 149 SOUTH KOREA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 150 SOUTH KOREA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 151 SOUTH KOREA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 152 SOUTH KOREA PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 153 SOUTH KOREA LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 154 SOUTH KOREA ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 155 SOUTH KOREA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 156 SOUTH KOREA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 157 SOUTH KOREA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 158 SOUTH KOREA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 159 SOUTH KOREA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 160 SOUTH KOREA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 161 SOUTH KOREA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 162 SOUTH KOREA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 163 SOUTH KOREA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 164 SOUTH KOREA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 165 SOUTH KOREA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 166 SOUTH KOREA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 167 SOUTH KOREA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 168 SOUTH KOREA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 169 SOUTH KOREA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 170 SOUTH KOREA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 171 SOUTH KOREA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 172 SOUTH KOREA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 173 SOUTH KOREA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 174 SOUTH KOREA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 175 SOUTH KOREA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 176 SOUTH KOREA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 177 SOUTH KOREA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 178 AUSTRALIA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 179 AUSTRALIA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 180 AUSTRALIA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 181 AUSTRALIA PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 182 AUSTRALIA LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 183 AUSTRALIA ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 184 AUSTRALIA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 185 AUSTRALIA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 186 AUSTRALIA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 187 AUSTRALIA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 188 AUSTRALIA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 189 AUSTRALIA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 190 AUSTRALIA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 191 AUSTRALIA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 192 AUSTRALIA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 193 AUSTRALIA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 194 AUSTRALIA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 195 AUSTRALIA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 196 AUSTRALIA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 197 AUSTRALIA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 198 AUSTRALIA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 199 AUSTRALIA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 200 AUSTRALIA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 201 AUSTRALIA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 202 AUSTRALIA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 203 AUSTRALIA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 204 AUSTRALIA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 205 AUSTRALIA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 206 AUSTRALIA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 207 TAIWAN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 208 TAIWAN PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 209 TAIWAN PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 210 TAIWAN PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 211 TAIWAN LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 212 TAIWAN ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 213 TAIWAN CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 214 TAIWAN SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 215 TAIWAN SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 216 TAIWAN HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 217 TAIWAN HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 218 TAIWAN ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 219 TAIWAN ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 220 TAIWAN LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 221 TAIWAN LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 222 TAIWAN BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 223 TAIWAN BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 224 TAIWAN CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 225 TAIWAN CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 226 TAIWAN PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 227 TAIWAN PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 228 TAIWAN CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 229 TAIWAN CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 230 TAIWAN CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 231 TAIWAN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 232 TAIWAN CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 233 TAIWAN HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 234 TAIWAN HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 235 TAIWAN CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 236 INDIA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 237 INDIA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 238 INDIA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 239 INDIA PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 240 INDIA LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 241 INDIA ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 242 INDIA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 243 INDIA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 244 INDIA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 245 INDIA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 246 INDIA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 247 INDIA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 248 INDIA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 249 INDIA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 250 INDIA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 251 INDIA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 252 INDIA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 253 INDIA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 254 INDIA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 255 INDIA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 256 INDIA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 257 INDIA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 258 INDIA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 259 INDIA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 260 INDIA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 261 INDIA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 262 INDIA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 263 INDIA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 264 INDIA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 265 INDONESIA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 266 INDONESIA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 267 INDONESIA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 268 INDONESIA PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 269 INDONESIA LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 270 INDONESIA ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 271 INDONESIA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 272 INDONESIA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 273 INDONESIA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 274 INDONESIA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 275 INDONESIA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 276 INDONESIA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 277 INDONESIA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 278 INDONESIA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 279 INDONESIA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 280 INDONESIA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 281 INDONESIA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 282 INDONESIA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 283 INDONESIA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 284 INDONESIA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 285 INDONESIA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 286 INDONESIA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 287 INDONESIA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 288 INDONESIA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 289 INDONESIA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 290 INDONESIA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 291 INDONESIA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 292 INDONESIA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 293 INDONESIA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 294 HONG KONG CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 295 HONG KONG PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 296 HONG KONG PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 297 HONG KONG PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 298 HONG KONG LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 299 HONG KONG ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 300 HONG KONG CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 301 HONG KONG SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 302 HONG KONG SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 303 HONG KONG HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 304 HONG KONG HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 305 HONG KONG ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 306 HONG KONG ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 307 HONG KONG LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 308 HONG KONG LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 309 HONG KONG BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 310 HONG KONG BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 311 HONG KONG CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 312 HONG KONG CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 313 HONG KONG PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 314 HONG KONG PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 315 HONG KONG CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 316 HONG KONG CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 317 HONG KONG CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 318 HONG KONG CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 319 HONG KONG CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 320 HONG KONG HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 321 HONG KONG HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 322 HONG KONG CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 323 NEW ZEALAND CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 324 NEW ZEALAND PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 325 NEW ZEALAND PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 326 NEW ZEALAND PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 327 NEW ZEALAND LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 328 NEW ZEALAND ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 329 NEW ZEALAND CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 330 NEW ZEALAND SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 331 NEW ZEALAND SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 332 NEW ZEALAND HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 333 NEW ZEALAND HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 334 NEW ZEALAND ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 335 NEW ZEALAND ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 336 NEW ZEALAND LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 337 NEW ZEALAND LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 338 NEW ZEALAND BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 339 NEW ZEALAND BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 340 NEW ZEALAND CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 341 NEW ZEALAND CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 342 NEW ZEALAND PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 343 NEW ZEALAND PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 344 NEW ZEALAND CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 345 NEW ZEALAND CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 346 NEW ZEALAND CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 347 NEW ZEALAND CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 348 NEW ZEALAND CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 349 NEW ZEALAND HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 350 NEW ZEALAND HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 351 NEW ZEALAND CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 352 SINGAPORE CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 353 SINGAPORE PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 354 SINGAPORE PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 355 SINGAPORE PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 356 SINGAPORE LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 357 SINGAPORE ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 358 SINGAPORE CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 359 SINGAPORE SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 360 SINGAPORE SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 361 SINGAPORE HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 362 SINGAPORE HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 363 SINGAPORE ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 364 SINGAPORE ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 365 SINGAPORE LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 366 SINGAPORE LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 367 SINGAPORE BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 368 SINGAPORE BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 369 SINGAPORE CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 370 SINGAPORE CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 371 SINGAPORE PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 372 SINGAPORE PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 373 SINGAPORE CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 374 SINGAPORE CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 375 SINGAPORE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 376 SINGAPORE CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 377 SINGAPORE CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 378 SINGAPORE HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 379 SINGAPORE HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 380 SINGAPORE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 381 PHILIPPINES CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 382 PHILIPPINES PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 383 PHILIPPINES PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 384 PHILIPPINES PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 385 PHILIPPINES LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 386 PHILIPPINES ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 387 PHILIPPINES CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 388 PHILIPPINES SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 389 PHILIPPINES SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 390 PHILIPPINES HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 391 PHILIPPINES HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 392 PHILIPPINES ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 393 PHILIPPINES ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 394 PHILIPPINES LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 395 PHILIPPINES LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 396 PHILIPPINES BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 397 PHILIPPINES BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 398 PHILIPPINES CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 399 PHILIPPINES CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 400 PHILIPPINES PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 401 PHILIPPINES PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 402 PHILIPPINES CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 403 PHILIPPINES CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 404 PHILIPPINES CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 405 PHILIPPINES CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 406 PHILIPPINES CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 407 PHILIPPINES HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 408 PHILIPPINES HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 409 PHILIPPINES CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 410 THAILAND CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 411 THAILAND PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 412 THAILAND PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 413 THAILAND PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 414 THAILAND LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 415 THAILAND ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 416 THAILAND CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 417 THAILAND SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 418 THAILAND SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 419 THAILAND HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 420 THAILAND HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 421 THAILAND ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 422 THAILAND ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 423 THAILAND LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 424 THAILAND LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 425 THAILAND BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 426 THAILAND BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 427 THAILAND CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 428 THAILAND CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 429 THAILAND PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 430 THAILAND PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 431 THAILAND CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 432 THAILAND CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 433 THAILAND CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 434 THAILAND CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 435 THAILAND CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 436 THAILAND HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 437 THAILAND HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 438 THAILAND CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 439 MALAYSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 440 MALAYSIA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 441 MALAYSIA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 442 MALAYSIA PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 443 MALAYSIA LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 444 MALAYSIA ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 445 MALAYSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 446 MALAYSIA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 447 MALAYSIA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 448 MALAYSIA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 449 MALAYSIA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 450 MALAYSIA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 451 MALAYSIA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 452 MALAYSIA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 453 MALAYSIA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 454 MALAYSIA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 455 MALAYSIA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 456 MALAYSIA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 457 MALAYSIA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 458 MALAYSIA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 459 MALAYSIA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 460 MALAYSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 461 MALAYSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 462 MALAYSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 463 MALAYSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 464 MALAYSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 465 MALAYSIA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 466 MALAYSIA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 467 MALAYSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 468 REST OF ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

Lista de Figura

FIGURE 1 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET: DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET: ASIA-PACIFIC VS REGIONAL ANALYSIS

FIGURE 5 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET: SEGMENTATION

FIGURE 10 EXECUTIVE SUMMARY

FIGURE 11 STRATEGIC DECISIONS

FIGURE 12 TWO SEGMENTS COMPRISE THE ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE (2024)

FIGURE 13 INCREASING PREVALENCE OF CANCER ACROSS GLOBE EXPECTED TO DRIVE THE ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET IN THE FORECAST PERIOD OF 2025 TO 2032

FIGURE 14 PHOTOSENSITIZER DRUGS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET IN 2025 & 2032

FIGURE 15 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET-MARKET OVERVIEW

FIGURE 16 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2024

FIGURE 17 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2024

FIGURE 18 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032

FIGURE 19 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032

FIGURE 20 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2024

FIGURE 21 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2024

FIGURE 22 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032

FIGURE 23 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032

FIGURE 24 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2024

FIGURE 25 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2024

FIGURE 26 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032

FIGURE 27 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032

FIGURE 28 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2024

FIGURE 29 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2024

FIGURE 30 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032

FIGURE 31 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032

FIGURE 32 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2024

FIGURE 33 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2024

FIGURE 34 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032

FIGURE 35 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032

FIGURE 36 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2024

FIGURE 37 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032

FIGURE 38 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032

FIGURE 39 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032

FIGURE 40 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2024

FIGURE 41 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2024

FIGURE 42 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032

FIGURE 43 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032

FIGURE 44 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024

FIGURE 45 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024

FIGURE 46 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032

FIGURE 47 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032

FIGURE 48 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET: SNAPSHOT (2024)

FIGURE 49 ASIA-PACIFIC CANCER PHOTODYNAMIC THERAPY MARKET: COMPANY SHARE 2024 (%)

View Detailed Information

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

Quais são os principais segmentos abordados no relatório Relatório sobre o tamanho, participação e tendências do mercado?

O mercado é segmentado com base em Mercado de Terapia Fotodinâmica para Câncer na Ásia-Pacífico, por Tipo de Produto (Medicamentos Fotossensibilizadores, Dispositivos de Terapia Fotodinâmica, Acessórios e Consumíveis), por Indicação de Câncer (Oncologia Cutânea e de Pele, Cabeça e Pescoço, Esôfago, Pulmão, Bexiga, Colo do Útero, Próstata), por Modalidade de Terapia (Terapia Isolada, Terapia Adjuvante, Terapia Paliativa, Terapia Combinada, Outras), por Técnica de Procedimento (Feixe Externo, Administração Intersticial, Administração Intracavitária, Administração Intraoperatória, Outras), por Estágio da Doença (Câncer em Estágio Inicial, Câncer em Estágio Avançado), por Perfil Demográfico do Paciente (Pediátrico, Adulto, Geriátrico), por Usuário Final (Hospitais, Clínicas de Dermatologia e Câncer de Pele, Centros Cirúrgicos Ambulatoriais, Institutos Acadêmicos e de Pesquisa, Outros), por Canal de Distribuição (Licitações Diretas, Distribuidores Terceirizados, Online, Outros) - Tendências e Previsões do Setor até 2032. .

Qual é o tamanho atual do mercado de Relatório sobre o tamanho, participação e tendências do mercado?

O tamanho do Relatório sobre o tamanho, participação e tendências do mercado foi avaliado em USD 738.34 USD Million no ano de 2024.

Qual é a taxa de crescimento esperada para Relatório sobre o tamanho, participação e tendências do mercado?

O Relatório sobre o tamanho, participação e tendências do mercado está projetado para crescer a um CAGR de 8.3% durante o período de previsão de 2025 a 2032.

Quem são os principais players do Relatório sobre o tamanho, participação e tendências do mercado?

Os principais players do mercado incluem Novartis Pharma AG ,Galderma SA ,Bausch Health Companies Inc. ,Photocure ASA ,ADVANZ PHARMA Corp. ,Sun Pharmaceutical Industries Ltd..

Relatório sobre o tamanho, participação e tendências do mercado de terapia fotodinâmica para o câncer na região Ásia-Pacífico – Visão geral do setor e previsão até 2032

Contorne os desafios das tarifas com uma consultoria ágil da cadeia de abastecimento

Asia Pacific Cancer Photodynamic Therapy Market

CAGR : 8.30 %

Tamanho do mercado de terapia fotodinâmica para câncer na região Ásia-Pacífico

Análise do Mercado de Terapia Fotodinâmica para Câncer na Região Ásia-Pacífico

Escopo do relatório e segmentação do mercado de terapia fotodinâmica para câncer na região Ásia-Pacífico

Principais informações sobre o mercado de seda na região Ásia-Pacífico

Tendências do mercado de terapia fotodinâmica para o câncer na região Ásia-Pacífico

Dinâmica do mercado de terapia fotodinâmica para o câncer na região Ásia-Pacífico

Escopo do mercado de terapia fotodinâmica para câncer na região Ásia-Pacífico

Análise Regional do Mercado de Terapia Fotodinâmica para o Câncer na Ásia-Pacífico

Últimos desenvolvimentos no mercado de terapia fotodinâmica para o câncer na região Ásia-Pacífico

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Índice

Lista de Tabela

Lista de Figura

Metodologia de Investigação

Personalização disponível

Perguntas frequentes

Relatórios

Informações de mercado

Apoiar

Soluções

Relatório sobre o tamanho, participação e tendências do mercado de terapia fotodinâmica para o câncer na região Ásia-Pacífico – Visão geral do setor e previsão até 2032

Contorne os desafios das tarifas com uma consultoria ágil da cadeia de abastecimento

Asia Pacific Cancer Photodynamic Therapy Market

CAGR : 8.30 %

Tamanho do mercado de terapia fotodinâmica para câncer na região Ásia-Pacífico

Análise do Mercado de Terapia Fotodinâmica para Câncer na Região Ásia-Pacífico

Escopo do relatório e segmentação do mercado de terapia fotodinâmica para câncer na região Ásia-Pacífico

Principais informações sobre o mercado de seda na região Ásia-Pacífico

Tendências do mercado de terapia fotodinâmica para o câncer na região Ásia-Pacífico

Dinâmica do mercado de terapia fotodinâmica para o câncer na região Ásia-Pacífico

Escopo do mercado de terapia fotodinâmica para câncer na região Ásia-Pacífico

Análise Regional do Mercado de Terapia Fotodinâmica para o Câncer na Ásia-Pacífico

Últimos desenvolvimentos no mercado de terapia fotodinâmica para o câncer na região Ásia-Pacífico

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Índice

Lista de Tabela

Lista de Figura

Metodologia de Investigação

Personalização disponível

Perguntas frequentes

Navegue pelas páginas relacionadas